



WE CLAIM:


1. A compound of the formula



or



wherein n is 0 to 4, R<sub>1</sub> and R<sub>2</sub>, which can be the same or different are H, OH, an alkoxy group of 1 to 4 carbon atoms, benzyloxy or methoxymethoxy; R<sub>3</sub> is H, OH, halogen, alkoxy of 1 to 4 carbon atoms, benzyloxy, methoxymethoxy, 2,3-dihydroxypropoxy or




wherein m is 1 or 2, R<sub>6</sub> and R<sub>7</sub>, which can be the same or different are H or an alkyl group of 1 to 4 carbon

atoms, or -N $\begin{matrix} \nearrow R_6 \\ \searrow R_7 \end{matrix}$  can form an N-containing three-, four-, five- or six-membered heterocyclic ring; R<sub>4</sub> is OH, F, Cl, Br, J, mesyloxy, tosyloxy, alkylcarbonyloxy of 1 to 4 carbon atoms, formyloxy or CH<sub>2</sub>R<sub>4</sub> is replaced by CHO; R<sub>5</sub> is H or OH; or R<sub>4</sub> and R<sub>5</sub> together form an -O- bridge between the carbon atoms to which they are attached, provided that

- a) when n is 0, then  $R_2$  and  $R_3$  are not both simultaneously hydrogen or methoxy
- b) when n is 0, then  $R_3$  must be other than halogen
- c) when n is 1 and  $R_4$  and  $R_5$  both are OH or together form an -O- bridge between the carbon atoms to which they are attached, then  $R_1$ ,  $R_2$  and  $R_3$  are not all simultaneously hydrogen
- d) when n is 2 and  $R_4$  and  $R_5$  together form an -O- bridge between the carbon atoms to which they are attached, then  $R_1$ ,  $R_2$  and  $R_3$  are not all simultaneously hydrogen

and their non-toxic pharmaceutically acceptable salts, N-oxides and esters and mixtures thereof.

2. A compound according to claim 1 wherein n is 1 or 2, each of  $R_1$ ,  $R_2$  and  $R_3$  is hydrogen, hydroxy, methoxy or ethoxy, at least one of  $R_1$ ,  $R_2$  and  $R_3$  being other than hydrogen, and  $R_3$  may in addition be



wherein  $R_6$  and  $R_7$  are methyl or ethyl,  $R_4$  is chlorine, bromine or hydroxy,  $R_5$  is hydrogen or hydroxy, or  $R_4$  and  $R_5$  together form an -O- bridge between the carbon atoms to which they are attached, and its non-toxic pharmaceutically acceptable salts and esters and mixtures thereof.

3. A compound according to claim 1 which is 1,2-diphenyl-1-(4-hydroxyphenyl)butane-1,4-diol and its non-toxic pharmaceutically acceptable salts and esters.
4. A compound according to claim 1 which is 2,3-diphenyl-2-(4-hydroxyphenyl)tetrahydrofuran and its non-toxic pharmaceutically acceptable salts and esters.
5. A compound according to claim 1 which is 1,2-diphenyl-1-(4-methoxyphenyl)-1-buten-4-ol and its non-toxic pharmaceutically acceptable esters.
6. A compound according to claim <sup>21</sup> 1 which is 1,2-diphenyl-1-[4-[2-(N,N-dimethylamino)ethoxy]phenyl]-1-buten-4-ol and its non-toxic pharmaceutically acceptable salts and esters.
7. A compound according to claim 1 which is 2,3-diphenyl-2-(4-hydroxyphenyl)tetrahydropyran and its non-toxic pharmaceutically acceptable salts and esters.
8. A compound according to claim 1 which is 1,2-diphenyl-1-(4-hydroxyphenyl)-1-penten-5-ol and its non-toxic pharmaceutically acceptable salts and esters.

29. A compound according to claim 1 which is 4-chloro-1,2-diphenyl-1-[4-[2-(N,N-dimethylamino)ethoxy]phenyl]-1-butene <sup>or a</sup> and its non-toxic pharmaceutically acceptable salts <sup>thereof</sup>.

10. A compound according to claim 1 which is 1-phenyl-1,2-bis-(4-hydroxyphenyl)butane-1,4-diol and its non-toxic pharmaceutically acceptable salts and esters.

N

P

N

K

CLAIMS

3-6

N


P

K


69

11. A compound according to claim 1 which is 2-phenyl-2,3-bis(4-hydroxyphenyl)tetrahydrofuran and its non-toxic pharmaceutically acceptable salts and esters. *B*
12. A compound according to claim 1 which is 1,2-diphenyl-1-(4-hydroxyphenyl)-1-buten-4-ol and its non-toxic pharmaceutically acceptable salts and esters.
- B C* 13. A compound according to claim <sup>21-24</sup> 1 which is 4-bromo-1,2-diphenyl-1-[4-[2-(N,N-dimethylamino)-ethoxy]-phenyl]-1-butene *2* and its non-toxic pharmaceutically acceptable salts.
14. A compound according to claim 1 which is 4-chloro-1,2-diphenyl-1-(4-hydroxyphenyl)butane and its non-toxic pharmaceutically acceptable salts and esters.
15. A compound according to claim 1 which is 4-chloro-1,2-diphenyl-1-(4-hydroxyphenyl)-1-butene and its non-toxic pharmaceutically acceptable salts and esters. *B*
16. A compound according to claim 1 which is 2,3-diphenyl-2-[4-[2-(N,N-dimethylamino)ethoxy]-phenyl]-tetrahydrofuran and its non-toxic pharmaceutically acceptable salts.
17. A compound according to claim 1 which is 1,2-diphenyl-1-[4-[2-(N,N-dimethylamino)ethoxy]-phenyl]-butane-1,4-diol and its non-toxic pharmaceutically acceptable salts and esters.


18. A pharmaceutical composition comprising an effective amount of a compound of the formula




or



wherein  $n$  is 0 to 4,  $\text{R}_1$  and  $\text{R}_2$ , which can be the same or different are H, OH, an alkoxy group of 1 to 4 carbon atoms, benzyloxy or methoxymethoxy;  $\text{R}_3$  is H, OH, halogen, alkoxy of 1 to 4 carbon atoms, benzyl-oxy, methoxymethoxy, 2,3-dihydroxypropoxy or



wherein  $m$  is 1 or 2,  $\text{R}_6$  and  $\text{R}_7$ , which can be the same or different are H or an alkyl group of 1 to 4 carbon atoms, or



can form an N-containing three-, four-, five- or six-membered heterocyclic ring;  $\text{R}_4$  is OH, F, Cl, Br, J, mesyloxy, tosyloxy, alkylcarbonyloxy of 1 to 4 carbon atoms, formyloxy or  $\text{CH}_2\text{R}_4$  is replaced by CHO;  $\text{R}_5$  is H or OH; or  $\text{R}_4$  and  $\text{R}_5$  together form an -O-bridge between the carbon atoms to which they are attached or a non-toxic pharmaceutically acceptable salt or ester thereof and a compatible pharmaceutically acceptable carrier therefor.

N  
P  
N  
K  
19. A method of producing an oestrogenic, anti-oestrogenic or progestanic effect in a subject in which such an effect is desired which comprises administering to said subject an effective amount of a compound ~~of formula (I) or (II)~~ <sup>24</sup> as defined in claim ~~18~~ <sup>24</sup> or a non-toxic pharmaceutically acceptable salt ~~or ester~~ thereof.

D  
7 ~~20~~ <sup>28</sup> 6. A method according to claim ~~19~~ <sup>28</sup> in which an anti-oestrogenic effect is produced in a subject suffering from an oestrogen-dependent tumour.

add  
B'

→ C2, D' × D2

CND